TGF-beta/SMAD Pathway and Its Regulation in Hepatic Fibrosis.
Xu F, Liu C, Zhou D, Zhang L.
J Histochem Cytochem. 2016 Mar;64(3):157-67. doi: 10.1369/0022155415627681. Epub 2016 Jan 8.
Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Khanam A, Saleeb PG, Kottilil S.
Cells. 2021 May 4;10(5):1097. doi: 10.3390/cells10051097.
Hepatic Fibrosis in Dogs.
Eulenberg VM, Lidbury JA.
J Vet Intern Med. 2018 Jan;32(1):26-41. doi: 10.1111/jvim.14891. Epub 2017 Nov 30.
Mangiferin relieves CCl4-induced liver fibrosis in mice.
Zhang L, Liu C, Yin L, Huang C, Fan S.
Sci Rep. 2023 Mar 13;13(1):4172. doi: 10.1038/s41598-023-30582-3.
Key Players of Hepatic Fibrosis.
Dawood RM, El-Meguid MA, Salum GM, El Awady MK.
J Interferon Cytokine Res. 2020 Oct;40(10):472-489. doi: 10.1089/jir.2020.0059. Epub 2020 Aug 25.
Relaxin in hepatic fibrosis: What is known and where to head?
Ezhilarasan D.
Biochimie. 2021 Aug;187:144-151. doi: 10.1016/j.biochi.2021.06.001. Epub 2021 Jun 5.
Hepatic Fibrosis: Emerging Therapies.
Friedman SL.
Dig Dis. 2015;33(4):504-7. doi: 10.1159/000374098. Epub 2015 Jul 6.
CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges.
Luo N, Zhong W, Li J, Lu J, Dong R.
Mol Biol Rep. 2022 Dec;49(12):11403-11408. doi: 10.1007/s11033-022-07713-6. Epub 2022 Aug 12.
Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.
Zhang X, Zeng Y, Zhao L, Xu Q, Miao D, Yu F.
Curr Drug Targets. 2023;24(7):568-583. doi: 10.2174/1389450124666230330135834.
Hepatic fibrosis -- overview.
Friedman SL.
Toxicology. 2008 Dec 30;254(3):120-9. doi: 10.1016/j.tox.2008.06.013. Epub 2008 Jul 10.
